Study: NCT03978143

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: 250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: 250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: 250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment F
Description: 250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment F
Description: 250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment F
Description: 250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment G
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment G
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment G
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment H
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment H
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment H
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.